Big Beat for Gilead on Rising Sovaldi Revenue

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

July 23 (Bloomberg) -- Gilead Sciences, maker of the hepatitis C pill Sovaldi, doubled its sales forecast for the year on better-than-estimated revenue from the blockbuster pill. Bloomberg’s Olivia Sterns reports on “Street Smart.” (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change